Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Cabozantinib + Durvalumab +/- Tremelimumab for Gastrointestinal Cancers
Recruiting1 awardPhase 1 & 2
Pittsburgh, Pennsylvania
This trial is testing the safety of combining two drugs to treat gastroesophageal cancer and other gastrointestinal cancers. The goal is to find a more effective therapy for these patients.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service